Company: IXHL
Filing Date: 2025-04-17
Form Type: PRER14A
Source: 0001213900-25-033013
Chunk: 16

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-17
Form: PRER14A
Chunk 16
---
 KY1-1001, Cayman Islands.                                                                                                     |

| (9) | Consist of 1,929,015 shares of common stock purchased in the Private Placement by S.H.N Financial Investments Ltd (“S.H.N”)              
 and excludes 1,929,015 shares of common stock (subject to the adjustment and alternative cashless exercise provisions of the Series A    
 Warrants) issuable upon the exercise of the Series A Warrants held by S.H.N, the exercise of which are subject to receipt of the Warrant 
 Stockholder Approval and certain beneficial ownership limitations. Nir Shamir and Hadar Shamir have shared power to vote and dispose of  
 the securities held by S.H.N and may be deemed to be the beneficial owners of such shares of common stock. The business address of S.H.N 
 is Arik Einstein 3, Herzliya, Israel.                                                                                                    |

| (10) | Consist of 1,929,015 shares of common stock purchased in the Private Placement by Great Point Capital, LLC (“Great Point”)                 
 and excludes 1,929,015 shares of common stock (subject to the adjustment and alternative cashless exercise provisions of the Series A      
 Warrants) issuable upon the exercise of the Series A Warrants held by Great Point, the exercise of which are subject to receipt of the     
 Warrant Stockholder Approval and certain beneficial ownership limitations. Dan Dimiero is the Manager of Great Point Capital and may be    
 deemed to beneficially own the securities held by it. The principal address of Great Point Capital is 200 West Jackson, Ste 1000, Chicago, 
 IL 60606.                                                                                                                                  |

<div align='center'>9

Proposal No. 1
APPROVAL OF THE ISSUANCE PROPOSAL</div>

Background

On March 10, 2025, we consummated the previously
announced private placement (the “Private Placement”) pursuant to securities purchase agreements (“Purchase Agreements”)
with certain institutional investors for the purchase and sale of an aggregate of 9,687,045 shares of our common stock at a price of $1.08
per share of common stock, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,887,045 shares of our common
stock (the “Pre-Funded Warrant Shares”) at a price of $1.0799 per Pre-Funded Warrant and Series A common stock warrants (the
“Series A Warrants